-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$62.3387.68% Upside
CG Oncology, Inc. Common stock Frequently Asked Questions
-
What analysts cover CG Oncology, Inc. Common stock?
CG Oncology, Inc. Common stock has been rated by research analysts at UBS, H.C. Wainwright, Goldman Sachs in the past 90 days.